Protein structure similarity clustering and natural product structure as guiding principles in drug discovery

Drug Discovery Today

Volumn 10, Issue 7, 2005, Pages 471-483

  Koch, Marcus A ^a   Waldmann, Herbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOPEPTIDASE; ANTIDIABETIC AGENT; ANTIESTROGEN; BENZOPYRAN DERIVATIVE; BESTATIN; CAPTOPRIL; CHENODEOXYCHOLIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; FARNESOID X RECEPTOR; GENISTEIN; GUGGULSTERONE; HORMONE RECEPTOR STIMULATING AGENT; HYDROLASE INHIBITOR; INSULIN SENSITIZING AGENT; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOTRANSFERASE INHIBITOR; PREGNANE X RECEPTOR; SULFOTRANSFERASE INHIBITOR; TAMOXIFEN; TROGLITAZONE; UNINDEXED DRUG;

CHOLESTASIS; COMBINATORIAL CHEMISTRY; DIABETES MELLITUS; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; ENZYME SPECIFICITY; GENOMICS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURAL GENOMICS; X RAY ANALYSIS;

BIOLOGICAL FACTORS; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, PROTEIN; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17044421362     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03419-7     Document Type: Review

References (91)

1. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 287:2000;1964-1969
2. Golebiowski A., et al. Lead compounds discovered from libraries. Curr. Opin. Chem. Biol. 5:2001;273-284
3. Mason J.S., Hermsmeier N.A. Diversity assessment. Curr. Opin. Chem. Biol. 3:1999;342-349
4. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol. Bioeng. 61:1998;61-67
5. Walters W.P., et al. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3:1999;384-387
6. Ajay A., et al. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J. Med. Chem. 41:1998;3314-3324
7. Sadowski J., Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41:1998;3325-3329
8. Ghose A.K., et al. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1:1999;55-68
9. Lee M.L., Schneider G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 3:2001;284-289
10. Breinbauer R., et al. From protein domains to drug candidates - natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. Engl. 41:2002;2879-2890
11. Koch M.A., et al. Protein structure similarity as guiding principle for combinatorial library design. Biol. Chem. 384:2003;1265-1272
12. Koch M.A., Waldmann H. Natural Product-derived Compound Libraries and Protein Structure Similarity as Guiding Principles for the Discovery of Drug Candidates. Kubinyi H., Müller G. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective. 2004;377-403 Wiley-VCH
13. Evans B.E., et al. Methods for drug discovery - development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:1988;2235-2246
14. Brohm D., et al. Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew. Chem. Int. Ed. Engl. 41:2002;307-311
15. Brohm D., et al. Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors. J. Am. Chem. Soc. 124:2002;13171-13178
16. Grishin N.V. Fold change in evolution of protein structures. J. Struct. Biol. 134:2001;167-185
17. Lupas A.N., et al. On the evolution of protein folds: are similar motifs in different protein folds the result of convergence, insertion, or relics of an ancient peptide world? J. Struct. Biol. 134:2001;191-203
18. Govindarajan S., et al. Estimating the total number of protein folds. Proteins. 35:1999;408-414
19. Ponting C.P., et al. Evolution of Domain Families. In Advances in Protein Chemistry. 54:2000;185-244
20. Murzin A.G., et al. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 247:1995;536-540
21. Andreeva A., et al. SCOP database in 2004: refinements integrate structure and sequence family data. Nucleic Acids Res. 32:2004;D226-D229
22. Orengo C.A., et al. Protein superfamilies and domain superfolds. Nature. 372:1994;631-634
23. Chothia C. Proteins - 1000 families for the molecular biologist. Nature. 357:1992;543-544
24. Zhang C.T. Relations of the numbers of protein sequences, families and folds. Protein Eng. 10:1997;757-761
25. Wang Z.X. A re-estimation for the total numbers of protein folds and superfamilies. Protein Eng. 11:1998;621-626
26. Zhang C.O., DeLisi C. Estimating the number of protein folds. J. Mol. Biol. 284:1998;1301-1305
27. Wolf Y.I., et al. Estimating the number of protein folds and families from complete genome data. J. Mol. Biol. 299:2000;897-905
28. Coulson A.F.W., Moult J. A unifold, mesofold, and superfold model of protein fold use. Proteins. 46:2002;61-71
29. Koonin E.V., et al. The structure of the protein universe and genome evolution. Nature. 420:2002;218-223
30. Weir M., et al. Insights into protein function through large-scale computational analysis of sequence and structure. Trends Biotechnol. 19:2001;S61-S66
31. Danchin A. From protein sequence to function. Curr. Opin. Struct. Biol. 9:1999;363-367
32. Tatusov R.L., et al. The COG database: new developments in phylogenetic classification of proteins from complete genomes. Nucleic Acids Res. 29:2001;22-28
33. Anantharaman V., et al. Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. Curr. Opin. Chem. Biol. 7:2003;12-20
34. Gerlt J.A., Babbitt P.C. Divergent evolution of enzymatic function: mechanistically diverse superfamilies and functionally distinct suprafamilies. Annu. Rev. Biochem. 70:2001;209-246
35. Todd A.E., et al. Evolution of protein function, from a structural perspective. Curr. Opin. Chem. Biol. 3:1999;548-556
36. Frye S.V. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol. 6:1999;R3-R7
37. Jacoby E., et al. Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect. 16:2003;93-102
38. Russell R.B., et al. Supersites within superfolds. Binding site similarity in the absence of homology. J. Mol. Biol. 282:1998;903-918
39. Koch M.A., et al. Compound library development guided by protein structure similarity clustering and natural product structure. Proc. Natl. Acad. Sci. U.S.A. 101:2004;16721-16726
40. Thunnissen M.M.G.M., et al. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. 8:2001;131-135
41. Rudberg P.C., et al. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J. Biol. Chem. 279:2004;27376-27382
42. Orning L., et al. Leukotriene A4 hydrolase - inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J. Biol. Chem. 266:1991;1375-1378
43. Yuan W., et al. Development of selective tight-binding inhibitors of leukotriene A4 hydrolase. J. Med. Chem. 36:1993;211-220
44. Ollmann I.R., et al. Investigation of the inhibition of leukotriene A4 hydrolase. Bioorg. Med. Chem. 3:1995;969-995
45. Hogg J.H., et al. Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. Bioorg. Med. Chem. 3:1995;1405-1415
46. Zhang M.Q. Leukotriene A4 hydrolase: a new target for anti-inflammatory intervention. Curr. Med. Chem. 4:1997;67-78
47. Thunnissen M.M.G.M., et al. Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 16:2002;1648-1650
48. Norman T.C., et al. A structure-based library approach to kinase inhibitors. J. Am. Chem. Soc. 118:1996;7430-7431
49. Gray N.S., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538
50. Chang Y.T., et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6:1999;361-375
51. Chang Y.T., et al. Purine-based inhibitors of inositol-1,4,5- trisphosphate-3-kinase. Chembiochem. 3:2002;897-901
52. Kakuta Y., et al. Crystal structure of estrogen sulphotransferase. Nat. Struct. Biol. 4:1997;904-908
53. Kakuta Y., et al. The sulfuryl transfer mechanism - crystal structure of a vanadate complex of estrogen sulfotransferase and mutational analysis. J. Biol. Chem. 273:1998;27325-27330
54. Armstrong J.I., et al. Discovery of carbohydrate sulfotransferase inhibitors from a kinase-directed library. Angew. Chem. Int. Ed. Engl. 39:2000;1303-1306
55. Verdugo D.E., et al. Discovery of estrogen sulfotransferase inhibitors from a purine library screen. J. Med. Chem. 44:2001;2683-2686
56. Chapman E., et al. A potent and highly selective sulfotransferase inhibitor. J. Am. Chem. Soc. 124:2002;14524-14525
57. Robinson-Rechavi M., et al. The nuclear receptor superfamily. J. Cell Sci. 116:2003;585-586
58. Schapira M. Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy. Curr. Cancer Drug Targets. 2:2002;243-256
59. Schapira M., et al. Rational discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1008-1013
60. Claudel T., et al. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs. 13:2004;1135-1148
61. Pike A.C.W., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18:1999;4608-4618
62. Dang Z.C., et al. Peroxisome proliferator-activated receptor gamma (PPAR gamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 278:2003;962-967
63. Van Gaal L., Scheen A.J. Are all glitazones the same? Diabetes Metab. Res. Rev. 18:(Suppl. 2):2002;S1-S4
64. Nicolaou K.C., et al. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 122:2000;9939-9953
65. Nicolaou K.C., et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10 000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 122:2000;9954-9967
66. Nicolaou K.C., et al. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 1:2003;908-920
67. Downes M., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell. 11:2003;1079-1092
68. Urizar N.L., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 296:2002;1703-1706
69. Bogan A.A., et al. Natural ligands of nuclear receptors have conserved volumes. Nat. Struct. Biol. 5:1998;679-681
70. Fauman E.B., et al. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell. 93:1998;617-625
71. Sussman J.L., et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 253:1991;872-879
72. Ibach B., Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr. Pharm. Des. 10:2004;231-251
73. Walker B.R., Seckl J.R. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets. 7:2003;771-783
74. Chrousos G.P. Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc. Natl. Acad. Sci. U.S.A. 101:2004;6329-6330
75. Schweizer R.A., et al. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol. Cell. Endocrinol. 212:2003;41-49
76. Masuzaki H., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2001;2166-2170
77. Masuzaki H., Flier J.S. Tissue-specific glucocorticoid reactivating enzyme, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) - a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3:2003;255-262
78. Paterson J.M., et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 101:2004;7088-7093
79. Alberts P., et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 45:2002;1528-1532
80. Ross S.A., et al. Chemistry and biochemistry of type 2 diabetes. Chem. Rev. 104:2004;1255-1282
81. Sandeep T.C., et al. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. U.S.A. 101:2004;6734-6739
82. New M.I., Wilson R.C. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc. Natl. Acad. Sci. U.S.A. 96:1999;12790-12797
83. Lyon M.A., et al. Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. 1:2002;961-976
84. Gunasekera S.P., et al. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 118:1996;8759-8760
85. Abreu P.M., Branco P.S. Natural product-like combinatorial libraries. J. Braz. Chem. Soc. 14:2003;675-712
86. Arya P., et al. Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age. Chem. Biol. 9:2002;145-156
87. Nicolaou K.C., Pfefferkorn J.A. Solid-phase synthesis of complex natural products and libraries thereof. Biopolymers. 60:2001;171-193
88. Barun O., et al. Asymmetric solid-phase synthesis of 6,6-spiroketals. Angew. Chem. Int. Ed. Engl. 43:2004;3195-3199
89. Holm L., Sander C. The FSSP database: fold classification based on structure-structure alignment of proteins. Nucleic Acids Res. 24:1996;206-209
90. Holm L., Sander C. Dali/FSSP classification of three-dimensional protein folds. Nucleic Acids Res. 25:1997;231-234
91. Shindyalov I.N., Bourne P.E. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng. 11:1998;739-747